Lexicon Pharmaceuticals, Inc.

Equities

LXRX

US5288723027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
1.77 ^USD	-3.80%		-1.12%	+15.69%

05-14	Transcript : Lexicon Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:00 AM
05-14	Lexicon Pharmaceuticals Says Post Hoc Analysis of Infepa Trial Showed Decreased Heart Failure Risk; Shares Gain Pre-Bell	MT

Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 02, 2024 at 04:05 pm

Lexicon Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 1.13 million compared to USD 0.024 million a year ago. Net loss was USD 48.4 million compared to USD 31.93 million a year ago.

Basic loss per share from continuing operations was USD 0.2 compared to USD 0.17 a year ago. Diluted loss per share from continuing operations was USD 0.2 compared to USD 0.17 a year ago.

Latest news about Lexicon Pharmaceuticals, Inc.

Transcript : Lexicon Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:00 AM	05-14
Lexicon Pharmaceuticals Says Post Hoc Analysis of Infepa Trial Showed Decreased Heart Failure Risk; Shares Gain Pre-Bell	05-14	MT
Lexicon Pharmaceuticals, Inc. Announces A New Post-Hoc Analysis of Clinical Data Showing That Inpefa® (Sotagliflozin), A Dual Oral Inhibitor of Sglt2 and Sglt1, Reduced the Risk of Heart Failure-Related Events Across A Diverse Population of Patients, Including Patients with Preserved Ejection Fraction	05-14	CI
Transcript : Lexicon Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024	05-02
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Posts Q1 Revenue $1.1M, vs. Street Est of $1.4M	05-02	MT
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Leerink Partners Starts Lexicon Pharmaceuticals With Outperform Rating, $5 Price Target	04-30	MT
Lexicon Pharmaceuticals' Chief Executive Lonnel Coats to Retire	04-29	MT
Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Member of Its Board of Directors, Effective July 7, 2024	04-29	CI
Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Chief Executive Officer, Effective from July 7, 2024	04-29	CI
Transcript : Lexicon Pharmaceuticals, Inc. - Analyst/Investor Day	04-22
Lexicon Pharmaceuticals Files Prospectus for Secondary Offering	03-25	MT
Lexicon Pharmaceuticals Shares Decline After Analysis Finds Similar Effect of Sotagliflozin in Type 1 Diabatic Patients	03-12	MT
Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease	03-12	CI
Health Care Dips Amid Regulatory Doubts -- Health Care Roundup	03-11	DJ
Sector Update: Health Care Stocks Softer Late Afternoon	03-11	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	03-11	MT
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Jump	03-11	MT
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Gain Pre-Bell	03-11	MT
Lexicon Pharmaceuticals Shares Rise on Beat to 4Q Loss, Plans for Sotagliflozin	03-11	DJ
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Reports Q4 Revenue $702,000	03-11	MT
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-11	CI
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-11	CI
Lexicon Pharmaceuticals, Inc Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA	03-11	CI
Lexicon Pharmaceuticals, Inc. announced that it expects to receive $249.99995 million in funding	03-10	CI

Chart Lexicon Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Lexicon Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.77 USD

Average target price

5.25 USD

Spread / Average Target

+196.61%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LEXICON PHARMACEUTICALS, INC.	+15.69%	665M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	114B
REGENERON PHARMACEUTICALS, INC.	+11.84%	104B
BIONTECH SE	-14.15%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.16%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.28B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.55B

Bio Therapeutic Drugs